Riskpilot← Back to searchSign inGet full accessNORSEPHARMA AS
ASActiveOrg 921105991Biskopshavn 1B, 5043 BergenRetail sale of other new goods · NACE 4778Est. 20180 employees
Revenue 2025
NOK 50K
-4% vs 2024
EBITDA margin
53.7%
-26% vs 2024
Equity ratio
88.9%
Financial strength
Net profit 2025
NOK 27K
-26% vs 2024
| Revenue | NOK 50K | -4% |
| EBITDA | NOK 27K | -26% |
| Net profit | NOK 27K | -26% |
| Total assets | NOK 117K | +36% |
| Equity | NOK 104K | +34% |
| Employees | 0 | — |
Legal name
NORSEPHARMA AS
Org number
921105991
Legal form
Aksjeselskap
NACE code
4778 · Retail sale of other new goods
Founded
2. august 2018
Share capital
NOK 40 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Daglig leder eller styrets leder alene.
Company purpose
Handel med kosttilskudd og relaterte produkter, produksjon og distribusjon samt aktuelle konsulent og rådgivningstjenester.
Address
Biskopshavn 1B, 5043 Bergen
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 50 | 52 | 50 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −14 | −15 | 36 | 36 | 27 |
| Depreciation & amort. | −22 | −0 | −0 | −0 | −0 |
| EBIT | −36 | −15 | 36 | 36 | 27 |
| Net financials | 0 | 0 | −0 | 0 | 0 |
| Profit before tax | −36 | −15 | 36 | 36 | 27 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −36 | −15 | 36 | 36 | 27 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 23 | 8 | 56 | 86 | 117 |
| Equity | 21 | 6 | 41 | 77 | 104 |
| Long-term debt | 0 | 0 | 4 | 0 | 0 |
| Short-term debt | 2 | 2 | 10 | 9 | 13 |
| Total debt | 2 | 2 | 14 | 9 | 13 |
EBITDA margin
53.7%
This company
15.8%
Market median
+240% vs market
20212025
Equity ratio
88.9%
This company
38.2%
Market median
+133% vs market
20212025
Return on equity
25.6%
This company
18.4%
Market median
+39% vs market
20212025
Net profit margin
53.7%
This company
8.1%
Market median
+563% vs market
20212025
Asset turnover
0.42×
This company
1.12×
Market median
-63% vs market
20212025
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
HR Chief Executive Officer | Chief Executive Officer | 2018 |
TJ Chief Executive Officer | Chief Executive Officer | 2024 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50% | 50% | 2022 | |
| Company | 50% | 50% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Røkke Invest As
NORSEPHARMA AS Board members of NORSEPHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Håvard Røkke | Chief Executive Officer | 0 companies |
| Tore Jakob Meltevik | Chief Executive Officer | 0 companies |